Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

New combination treatment for hepatitis C reported more beneficial than standard therapy

27.09.2002


he New England Journal of Medicine’s Sept. 26 issue carries the first published report showing that a combination treatment with peginterferon alfa-2a (Pegasys) - a new long-acting interferon drug - and an antiviral medication is more beneficial than the standard combination therapy for people with the most-difficult-to-treat and most common strain of hepatitis C.



The large international study, headed by researchers at the University of North Carolina at Chapel Hill, is also the first published one to show that treatment with the investigational drug peginterferon alfa-2a in combination with the oral antiviral medication, ribavirin, is linked to a lower rate of troublesome side effects - depression, flu-like symptoms (chills, headache and fever) - than the standard interferon (Rebetron) and ribavirin.

"Sixty-five percent of patients in the study were infected with hepatitis C genotype 1, the most prevalent genotype we see here in the United States, and typically the least responsive to therapy," said study co-author Dr. Michael W. Fried, associate professor of medicine and director of clinical hepatology at the UNC School of Medicine.


"With this research, we’ve found the most significant evidence to date suggesting these patients might benefit by taking peginterferon alfa-2a in combination with ribavirin."

According to Fried, side effects of therapy can be very challenging for patients. "The study shows an approach that can offer patients superior efficacy without increases in some of the most common and difficult to tolerate adverse events associated with hepatitis C therapy."

Of the six different strains, or genotypes, of hepatitis C, approximately 70 percent of people in North America are infected with genotype 1.

The study was funded by Hoffmann-La Roche, the maker of Pegasys, and was conducted at 81 clinical sites in 18 countries. More than 1,100 patients were involved in one of three study arms: 453 were treated with peginterferon alfa-2a plus oral ribavirin, 224 with peginterferon alfa-2a plus placebo and 444 with interferon alfa-2b plus ribavirin. Patients were treated for 48 weeks and then monitored for an additional 24 weeks.

A key variable measured by the study was sustained viral response, defined as undetectable serum hepatitis C RNA after the treatment-free follow-up period.

Overall, patients treated with the peginterferon alfa-2a plus ribavirin combination achieved a 56 percent sustained response rate as compared to patients taking Rebetron (44 percent). Patients with genotype 1 had a sustained response rate of 46 percent, compared to patients on Rebetron (36 percent) and those on Pegasys plus placebo (21 percent).

A retrospective analysis of the data showed that response to PEG interferon alpha-2a plus ribavirin is predictable. At week 12, 86 percent of patients treated with PEG interferon demonstrated an early viral response; of these, 65 percent attained a sustained viral response. However, 97 percent of patients who did not respond by week 12 failed to achieve a sustained response.

"This means that physicians can create an alternate treatment plan for patients who do not show any response by week 12," said Fried. "And for those who do respond, it can be a motivation to continue to adhere to their treatment regimens."

Dr. Fried added that these treatment decisions must be individualized for each patient.

The hepatitis C virus is a life-threatening viral infection of the liver transmitted primarily through infected blood and blood products. Approximately 2.7 million Americans and 170 million people worldwide are chronically infected with the virus, which is often described as "silent" because people may be infected for 10 to 30 years and not exhibit symptoms, yet still be carrying the virus.

While many patients with the hepatitis C virus will not develop complications from their liver disease, chronic hepatitis C is still a leading cause of cirrhosis and liver cancer and is the major indication for liver transplants in this country.

The UNC Center for Liver Diseases and Transplantation provides highly specialized care for liver diseases for residents of North Carolina and surrounding regions. In addition to its commitment to patient care, the UNC liver program is dedicated to studying novel therapies for viral hepatitis, other chronic liver diseases and transplantation.


Contact note: Fried is available at (919) 966-8784 or mfried@med.unc.edu

Leslie Lang | EurekAlert!
Further information:
http://www.med.unc.edu/

More articles from Health and Medicine:

nachricht Study shows novel protein plays role in bacterial vaginosis
13.12.2019 | University of Arizona Health Sciences

nachricht Illinois team develops first of a kind in-vitro 3D neural tissue model
12.12.2019 | University of Illinois College of Engineering

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: Virus multiplication in 3D

Vaccinia viruses serve as a vaccine against human smallpox and as the basis of new cancer therapies. Two studies now provide fascinating insights into their unusual propagation strategy at the atomic level.

For viruses to multiply, they usually need the support of the cells they infect. In many cases, only in their host’s nucleus can they find the machines,...

Im Focus: Cheers! Maxwell's electromagnetism extended to smaller scales

More than one hundred and fifty years have passed since the publication of James Clerk Maxwell's "A Dynamical Theory of the Electromagnetic Field" (1865). What would our lives be without this publication?

It is difficult to imagine, as this treatise revolutionized our fundamental understanding of electric fields, magnetic fields, and light. The twenty original...

Im Focus: Highly charged ion paves the way towards new physics

In a joint experimental and theoretical work performed at the Heidelberg Max Planck Institute for Nuclear Physics, an international team of physicists detected for the first time an orbital crossing in the highly charged ion Pr⁹⁺. Optical spectra were recorded employing an electron beam ion trap and analysed with the aid of atomic structure calculations. A proposed nHz-wide transition has been identified and its energy was determined with high precision. Theory predicts a very high sensitivity to new physics and extremely low susceptibility to external perturbations for this “clock line” making it a unique candidate for proposed precision studies.

Laser spectroscopy of neutral atoms and singly charged ions has reached astonishing precision by merit of a chain of technological advances during the past...

Im Focus: Ultrafast stimulated emission microscopy of single nanocrystals in Science

The ability to investigate the dynamics of single particle at the nano-scale and femtosecond level remained an unfathomed dream for years. It was not until the dawn of the 21st century that nanotechnology and femtoscience gradually merged together and the first ultrafast microscopy of individual quantum dots (QDs) and molecules was accomplished.

Ultrafast microscopy studies entirely rely on detecting nanoparticles or single molecules with luminescence techniques, which require efficient emitters to...

Im Focus: How to induce magnetism in graphene

Graphene, a two-dimensional structure made of carbon, is a material with excellent mechanical, electronic and optical properties. However, it did not seem suitable for magnetic applications. Together with international partners, Empa researchers have now succeeded in synthesizing a unique nanographene predicted in the 1970s, which conclusively demonstrates that carbon in very specific forms has magnetic properties that could permit future spintronic applications. The results have just been published in the renowned journal Nature Nanotechnology.

Depending on the shape and orientation of their edges, graphene nanostructures (also known as nanographenes) can have very different properties – for example,...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

VideoLinks
Industry & Economy
Event News

The Future of Work

03.12.2019 | Event News

First International Conference on Agrophotovoltaics in August 2020

15.11.2019 | Event News

Laser Symposium on Electromobility in Aachen: trends for the mobility revolution

15.11.2019 | Event News

 
Latest News

Supporting structures of wind turbines contribute to wind farm blockage effect

13.12.2019 | Physics and Astronomy

Chinese team makes nanoscopy breakthrough

13.12.2019 | Physics and Astronomy

Tiny quantum sensors watch materials transform under pressure

13.12.2019 | Materials Sciences

VideoLinks
Science & Research
Overview of more VideoLinks >>>